- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Research on Induced Pluripotent and Embryonic Stem Cells 'Inextricably Intertwined'
10 June 2011 2:41 pm
A new literature analysis confirms what stem cell scientists have been saying for some time: Studies of induced pluripotent stem cells (iPSCs), which are touted as an ethical alternative to human embryonic stem cells (hESCs), often involve hESCs as well. As a result, research that restricts funding for hESCs would also harm iPSC research.
HESCs are derived from human embryos, while iPSCs are made by reprogramming adult cells. In a study in the 10 June issue of Cell, Stanford University bioethicist Christopher Thomas Scott and colleagues analyze 2086 publications on hESCs and iPSCs from 1998 through 2010. While the number of publications using iPSCs has shot up since the first report on these cells in 2007, 100 of 161 iPSC papers (62%) published last year used both types of cells. Established investigators in particular tended to include hESCs, which are often used as controls.
Many researchers are worried that a lawsuit claiming federally funded hESC research violates a ban on research that destroys human embryos could stymie their work. The authors say that any decision by the courts or by legislators to limit funding for hESCs "will also have disastrous consequences for [iPSC funding] because research using the two different types of cell lines is deeply, perhaps inextricably, intertwined."